This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Gram-Negative Bacterial Infections
and you are
over 18
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The purpose of this study is to determine whether the addition of meropenem to colistin is better than colistin alone in the treatment of clinically significant infections caused by multi-drug resistant bacteria

Provided treatments

  • Drug: Colistin
  • Drug: Meropenem
Tris trial is registered with FDA with number: NCT01732250. The sponsor of the trial is Mical Paul and it is looking for 406 volunteers for the current phase.
Official trial title:
Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem